

## New and Recent Assays Available from *Specialty*

Effective date as noted

### 4911 Alpha-Fetoprotein-L3% (AFPL-3%) (effective 07/11/06)

Component	Method	Reference Range	Units
AFPL-3%	Liquid-Phase Binding Assay	<10 negative (actual percentage reported) >10 positive	% %
Specimen/Stability	5.0 (3.0) mL Serum; Ambient 5 days, Refrigerated 5 days, Frozen 1 month		
Clinical Utility	AFPL-3% is a useful tool for the early detection of hepatocellular carcinoma (HCC) in subjects with chronic hepatitis or liver cirrhosis. With a specificity greater than 92%, the test has proven to be a better marker for HCC than total Alpha-Fetoprotein (AFP) and becomes elevated approximately 21 months before detection of clinical disease.		
Performance Schedule	Set-up: Wednesday	Reported: within 8 days	
CPT Code	82105		

### 5390 JAK2 GenotypR™ (effective 6/21/06)

Component	Method	Reference Range	Units
JAK-2	real-time PCR	By report	
Specimen/Stability	5.0 (3.0) mL EDTA Whole Blood; Ambient 7 days, Refrigerated 7 days		
Alternate Specimens	1.5 (0.5) mL EDTA Bone Marrow; Ambient 7 days, Refrigerated 7 days		
Unacceptable specimens	Frozen or clotted specimens		
Collection Instructions	Collect whole blood or bone marrow in EDTA. Heparin is not recommended. Specimens will be stabilized upon departmental receipt.		
Clinical Utility	A majority of patients with polycythemia vera and a significant number of patients with essential thrombocythemia and myeloid metaplasia with myelofibrosis have a clonal acquired somatic JAK-2 activating mutation (exon 12 1849G>T (V617F)). Identification of this mutation in myeloproliferative disorders (MPD) may be useful to distinguish MPD from various reactive conditions, triage patients for further work-up and assess treatment options. The aberrant tyrosine kinase may be a viable target for pharmacologic treatment.		
Performance Schedule	Set-up: Monday-Thursday	Reported: within 3 days	
CPT Code	83891, 83900, 83914x2, 83912		
Notes	<p><b>NEW YORK CLIENTS:</b> Please continue to use test code #S51023NY JAK-2 V617 Mutation</p> <p>Reference: Baxter, EJ. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. <i>Lancet</i> 2005;365:1054-61.</p> <p>Kralovics, R. A gain-of-function mutation of JAK2 in myeloproliferative disorders. <i>N Engl J Med</i> 2005; 352:1779-90.</p>		

**DISCONTINUE: #S51074 JAK-2 V617 Mutation** sendout test discontinued effective July 5, 2006.

For additional information, please visit our Web site at [www.specialtylabs.com](http://www.specialtylabs.com) or contact Client Services at 800-421-4449.



Michael C. Dugan, M.D.  
 Vice President and Laboratory Director